Inositol + Selenium supplement can help patients with thyroiditis
- Lizette Rios
- Dec 22, 2017
- 5 min read
Introduction
This study used a combination of Inositol + Selenium supplements to restore the function to the thyroid of Hashimoto’s patients with subclinical hypothyroidism (mild thyroid failure).
There was one patient with hyperthyroidism that was also treated with the supplements.
Terminology:
Hashimoto’s disease – the patient’s immune system attacks the thyroid gland (located in the neck).
Hypothyroidism – underproduction of a hormone by the thyroid gland.
Hyperthyroidism – overproduction of a hormone by the thyroid gland.
Antibody – used by the immune system to identify foreign material in the body to attack and dispose of it.
Autoantibodies – is a type of antibody made by the immune system that signals it to attack itself.
Thyroid-stimulating hormone (TSH) – controls the release of hormones in the thyroid. It is needed for the growth and development of human cells, and also helps maintain a stable metabolism.
Methods
*Supplement name: Tiroxil®, Lo.Li. Pharma Srl, Rome, Italy
mcg = microgram
*Selenium in the form of L-selenomethionine
*Myo-Inositol = Inositol
*There was no placebo group, they analyzed chemical markers of the patient’s pre-treatment and post-treatment (before supplementation and after supplementation).
A placebo is a harmless pill that has no physiological effect on the individual, it is used to compare results with the treatment group.
Results
They found that Inositol + Selenium treatment for Hashimoto’s patients with hypothyroidism did the following:
1. Decreased:
a. Autoantibody levels – decreasing autoantibodies prevents the immune system from attacking the body.
b. Thyroid-stimulating hormone (TSH) – decreasing TSH levels to normal is helpful because Hashimoto’s patients will increase levels of TSH to compensate for the attack from the immune system.
2. Increased:
a. Hormones secreted by the thyroid – this is necessary because Hashimoto’s patients may not be able to secrete hormones needed due to a faulty thyroid.
b. Quality of life
They found that Inositol + Selenium treatment for the hyperthyroid patient did the following:
Increased:
a. Thyroid-stimulating hormone (TSH) levels to normal
b. Quality of life
Conclusion
Supplementing with Inositol + Selenium improved function of the thyroid of Hashimoto’s patients with subclinical hypothyroidism (mild thyroid failure).
The one patient with hyperthyroidism that was given the supplement also saw benefits that improved their quality of life and hormone levels.
Reflection
This study had a large number of patients and was for a long duration (6 months).
These combinations of supplements seem to be effective in improving the function of the thyroid for hypothyroidism and hyperthyroidism.
The one patient with a hyperthyroid provided great data, but a larger sample size is required to establish whether it may be significantly beneficial or not.
Website for the company that manufactures the supplement:
It seems as if the patent is still pending, I have sent the company a message on how and if the supplement can be purchased and will post their response.
*Inositol (600 mg) and Selenium (100 mcg) can be purchased online separately.
Be sure that Selenium is in the form of L-selenomethionine (will be available on the supplement facts).
*Before consuming supplements, consult with a physician, individuals can be affected differently.
Sources
Scientific Article courtesy of:
Nordio, M, and S Basciani. “Treatment with Myo-Inositol and Selenium Ensures Euthyroidism in Patients with Autoimmune Thyroiditis.” International journal of endocrinology., U.S. National Library of Medicine, www.ncbi.nlm.nih.gov/pubmed/28293260.
Image courtesy of:
“Thyroiditis - Types, Causes, Symptoms, Diagnosis, Treatment.” Medindia, 14 Dec. 2017, www.medindia.net/patientinfo/thyroiditis.htm.
Image courtesy of:
“Symptoms Causes and Treatment of Thyroiditis.” YouTube, YouTube, 26 Dec. 2016, www.youtube.com/watch?v=OAbVlblGXm4.
J. Orgiazzi, “Thyroid autoimmunity,” La Presse Médicale, vol. 41, no. 12, pp. 611–625, 2012.
F. Menconi, A. Hasham, and Y. Tomer, “Environmental triggers of thyroiditis: hepatitis C and interferon-α,” Journal of Endocrinological Investigation, vol. 34, no. 1, pp. 78–84, 2011.
Y. Tomer, “Genetic susceptibility to autoimmune thyroid disease: past, present, and future,” Thyroid, vol. 20, no. 7, pp. 715–725, 2010.
E. Ron and A. Brenner, “Non-malignant thyroid diseases after a wide range of radiation exposures,” Radiation Research, vol. 174, no. 6, pp. 877–888, 2010.
E.C.Somers,S.L.Thomas,L.Smeeth,andA.J.Hall,“Autoim- mune diseases co-occurring within individuals and within families: a systematic review,” Epidemiology, vol. 17, no. 2, pp. 202–217, 2006.
A. M. Nada and M. Hammouda, “Immunoregulatory T cells, LFA-3 and HLA-DR in autoimmune thyroid diseases,” Indian Journal of Endocrinology and Metabolism, vol. 18, no. 4, pp. 574–581, 2014.
D. S. Cooper and B. Biondi, “Subclinical thyroid disease,” The Lancet, vol. 379, no. 9821, pp. 1142–1154, 2012.
M. P. Thomas, S. J. Mills, and B. V. Potter, “The ‘other’ inositols and their phosphates: synthesis, biology, and medicine (with recent advances in myo-inositol chemistry),” Angewandte Chemie International Edition, vol. 55, no. 5, pp. 1614–1650, 2016.
T. G. Kutateladze, “Translation of the phosphoinositide code by PI effectors,” Nature Chemical Biology, vol. 6, no. 7, pp. 507–513, 2010.
M. Bizzarri and G. Carlomagno, “Inositol: history of an effective therapy for polycystic ovary syndrome,” European Review for Medical and Pharmacological Sciences, vol. 18, no. 13, pp. 1896–1903, 2014.
A.OettingandP.M.Yen,“Newinsightsintothyroidhormone action,” Best Practice & Research: Clinical Endocrinology & Metabolism, vol. 21, no. 2, pp. 193–208, 2007.
J. DeRuiter, “Thyroid hormone tutorial: the thyroid and thyroid hormones,” Endocrine Pharmacotherapy Module: Thyroid Section, Summer, 2001, 2002:5260, pp. 1–16, 2001.
V. Fatourechi, “Demystifying autoimmune thyroid disease. Which disorders require treatment?” Postgraduate Medicine, vol. 107, no. 1, pp. 127–134, 2000.
V. Fatourechi, “Subclinical hypothyroidism: an update for primary care physicians,” Mayo Clinic Proceedings, vol. 84, no. 1, pp. 65–71, 2009.
L. Wartofsky and R. A. Dickey, “The evidence for a narrower thyrotropin reference range is compelling,” The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 9, pp. 5483–5488, 2005.
R. Gartner, B. C. Gasnier, J. W. Dietrich, B. Krebs, and M. W. Angstwurm, “Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase anti- bodies concentrations,” Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 4, pp. 1687–1691, 2002.
J. Köhrle, “Selenium and the thyroid,” Current Opinion in Endocrinology, Diabetes, and Obesity, vol. 20, no. 5, pp. 441–448, 2013.
E. E. Mazokopakis, J. A. Papadakis, M. G. Papadomanolaki et al., “Effects of 12 months treatment with L-selenomethionine on serum anti-TPO levels in patients with Hashimoto’s thyroiditis,” Thyroid, vol. 17, no. 7, pp. 609–612, 2007.
D. Nacamulli, C. Mian, D. Petricca et al., “Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis,” Clinical Endocrinology, vol. 73, no. 4, pp. 535–539, 2010.
E. N. Pearce, A. P. Farwell, and L. E. Braverman, “Thyroiditis,” The New England Journal of Medicine, vol. 348, no. 26, pp. 2646–2655, 2003.
M. Nordio and R. Pajalich, “Combined treatment with myo- inositol and selenium ensures euthyroidism in subclinical hypothyroidism patients with autoimmune thyroiditis,” Journal of Thyroid Research, vol. 2013, Article ID 424163, 5 pages, 2013.
Commentaires